Long‐term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Medicine"
DOI: 10.1002/cam4.1104
Abstract: The use of neoadjuvant chemotherapy or radiation for borderline resectable pancreatic adenocarcinoma (BL‐PDAC) is increasing. However, the impact of neoadjuvant chemotherapy and radiation therapy on the outcome of BL‐PDAC remains to be elucidated. We performed… read more here.
Keywords: chemotherapy; upfront chemotherapy; received upfront; neoadjuvant chemotherapy ... See more keywords